Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M709030200 on February 11, 2008

J. Biol. Chem., Vol. 283, Issue 17, 11176-11188, April 25, 2008
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/17/11176    most recent
M709030200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chuderland, D.
Right arrow Articles by Seger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chuderland, D.
Right arrow Articles by Seger, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Calcium-mediated Interactions Regulate the Subcellular Localization of Extracellular Signal-regulated Kinases*

Dana Chuderland{ddagger}1, Goldie Marmor{ddagger}1, Alla Shainskaya§, and Rony Seger{ddagger}2

From the {ddagger}Department of Biological Regulation and §Mass Spectroscopy Unit, The Weizmann Institute of Science, Rehovot 76100, Israel

Received for publication, November 2, 2007 , and in revised form, February 8, 2008.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The subcellular localization of ERKs in cells, which is important for proper signaling, may be regulated through protein-protein interactions. We found that inactive ERK2 interacts with a large number of proteins through its cytosolic retention sequence/common docking domain, whereas the phospho-ERK2 interacts with only few substrates. Varying calcium concentrations significantly modified the repertoire of ERK2-interacting proteins, of which many were identified. The effect of calcium on ERK interactions also influenced the localization of ERKs, as calcium chelators enhanced nuclear translocation, whereas elevated calcium levels prevented it. This effect of calcium was apparent upon lysophosphatidic acid stimulation, where ERKs translocation was delayed compared with that induced by EGF in a calcium-dependent manner. In vitro translocation assay revealed that high calcium concentrations affect ERK translocation by preventing the shuttling machinery through the nuclear envelope, probably due to higher binding to nuclear pore proteins. These results are consistent with a model in which ERKs in quiescent cells are bound to several cytoplasmic proteins. Upon stimulation, ERKs are phosphorylated and released from cytoplasmic anchors to allow shuttling toward the nucleus. This translocation is delayed when calcium levels are increased, and this modifies the localization of ERKs and, therefore, also their spatiotemporal regulation. Thus, calcium regulates ERK localization, which is important for the compartmentalization of ERKs with their proper substrates and thereby their signaling specificity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The ERK3 cascade, which is a central and ubiquitous signaling pathway, utilizes Raf kinases MEKs and ERKs as its kinase components (1–3). Three isoforms of ERKs are currently known, ERK1, ERK2, and ERK1b/c (4–6), which upon extracellular stimulation are activated by MEK1 and MEK2. In resting cells MEKs and ERKs seem to interact with each other due to several regions in both molecules. The main interaction site of MEK in ERK seems to be the cytosolic retention sequence (CRS)/common docking (CD) domain in the C terminus of ERKs (7, 8). This site, operating together with additional domains in ERKs, is responsible for the levels of ERK phosphorylation (9) as well as subcellular localization. The CRS/CD domain of ERKs was reported to exert its functions mainly by interaction with many proteins including ERK substrates, and thereby the domain is responsible for the phosphorylation of many ERK targets. Interestingly, the regulators and the substrates may compete for the interaction with the CRS/CD domain and, thus, provide an additional facet to the regulation of ERK function (10).

One of the key steps in the regulation of the ERK cascade is an inducible change in the subcellular localization of its components. In resting cells, the components of the ERK cascade are localized primarily in the cytoplasm, but this is rapidly changed upon activation when MEKs and ERKs translocate into the nucleus. Whereas ERKs are transiently retained in the nucleus for minutes to hours (11), MEKs are rapidly exported from that location due to their nuclear export signal (12, 13). The accumulation of ERKs in the nucleus is important for proper activity of the ERK cascade and its cellular responses (14). Over the past years ERKs were found to be retained in the cytoplasm of quiescent cells by several proteins and organelles. One group of anchoring moieties confers an irreversible interaction (e.g. microtubules (15)), whereas another set allows a stimulus-dependent dissociation (MEKs (16), PTP-SL (17), KSR (18)). These interactions are a main cause of the homogeneous cytoplasmic distribution of ERKs in resting cells.

Upon stimulation, ERKs are detached from many of the cytoplasmic anchors including MEKs by a mechanism that involves conformational change of the activation loop of ERKs (19), and this allows a rapid nuclear translocation. However, the mechanisms that regulate this translocation are not fully understood, as the ERKs do not have a nuclear localization signal in their sequence. Thus, several distinct mechanisms that may participate in the translocation have been suggested (20), including direct interaction with nuclear pore proteins (NUPs (21, 22)). The presence of ERKs in the nucleus seems to be governed by two separate mechanisms; one is de novo synthesis of nuclear anchoring proteins (11), and the other is an exportin-mediated MEK-dependent nuclear export (23). Therefore, the subcellular localization of ERKs is governed by several docking interactions with proteins in the cytoplasm, nuclear pores, and the nucleus. Elucidation of all these interacting proteins may reveal new aspects of the regulation of signaling through the ERK cascade.

Stimulation of ERK activity is induced by various extracellular agents, including growth factors and hormones (4). In many systems, this stimulation is mediated or affected by elevation of intracellular calcium levels. Calcium is a versatile second messenger that affects many signaling processes in the cell (24, 25). The involvement of elevated calcium in activation of the ERK cascade has been studied mainly in neurons but also in other cell types (26–28). Several molecular mechanisms have been implicated in the calcium-dependent transmission of signals to ERKs. Thus, in EGF-stimulated vascular smooth muscle cells, elevated calcium levels induce activation of the ERK cascade through CaMKII, which is dependent on PYK2 and Src activation (29). Moreover, PYK2 (30) and CaMKII (31) were reported to stimulate ERKs upon calcium elevation independently of each other. Another calcium mediator that may induce ERKs activation is CaMKI that was shown to operate upon depolarization of neuroblastoma cells. Finally, the activation of ERKs by calcium can be mediated by RAS-GRP, which is a Ras guanyl nucleotide-releasing protein with calcium and diacylglycerol binding motifs (32). These studies show that ERKs can be affected by calcium and participate in the transmission of signals that induce high calcium concentrations.

During a study that was aimed at identifying ERK2 interactions, we found that inactive ERK2 interacts with many proteins through its CRS/CD domain, whereas pERK2 interacts with fewer targets. We then looked for factors that may modulate the interactions and found that changes in calcium concentrations profoundly modified the repertoire of bound proteins, which included cytoskeletal and ribosomal proteins, ERKs effectors, and others. EGF treatment, which only slightly increases calcium concentrations, did not affect the ERK2 interactions, suggesting that the phosphorylation of ERKs and not of their substrates is important for the interaction. Because protein-protein interactions play a role in determining the subcellular localization of ERKs, we examined this distribution upon modification of calcium concentrations. We found that calcium chelators enhanced nuclear translocation, whereas calcium ionophores prevented this translocation. A possible physiological effect of calcium on ERK signaling was shown with lysophosphatidic acid (LPA) that profoundly increases calcium concentration in Rat1 cells. This increment delayed the nuclear translocation of ERKs as compared with translocation induced by EGF. This effect of LPA occurred in a calcium-dependent manner as it was modified by calcium chelation. The molecular mechanism of the calcium effect is likely to be induced by inhibition of nuclear pore transport, as we found that ERKs are tightly bound to NUPs upon elevation of calcium concentration. We propose that high calcium levels prevent the nuclear shuttling and, therefore, play an important role in compartmentalizing ERKs. This allows interactions of ERKs with their proper substrates under varying physiological conditions and thereby determines the signaling specificity of the ERK cascade.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—Epidermal growth factor, ionomycin, bovine serum albumin, LPA, monoclonal anti-pERK and protein kinase C and polyclonal anti-ERK, -MEK, -RSK, -KSR, -MKP1, -MKP3, p38MAPK, and -CaMKII antibodies (Abs) were from Sigma. Polyclonal anti-pElk-1, -Elk-1, -phosphorylated MEK, -phosphorylated RSK, -Lyn, -Fyn, -protein kinase D, -p27KIP, -peroxisome proliferator-activated receptor {gamma}, -c-Fos, β-arrestin, and -actin Abs were from Santa Cruz Biotechnology, Inc. Anti-tubulin and vinculin Abs and purified vinculin were gifts from Dr. Benny Geiger from the Weizmann Institute, Rehovot, Israel, and hnRNP-K was a gift from Dr. Karol Bomsztyk from the University of Washington (Seattle, WA). BAPTA-AM, alkaline phosphatase-, peroxidase-, and lissamine rhodamine-conjugated secondary Abs were from Jackson Immunoresearch. Digitonin was purchased from Calbiochem, nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate was from Promega, and the ECL kit was from Amersham Biosciences. Recombinant NUP153 was a gift from Dr. Michael Elbaum from the Weizmann Institute of Science. MEK1 was prepared as previously reported (12), and recombinant Elk1 was from Cell Signaling. Glutathione beads were from Amersham Biosciences, and Gelcode was from Pierce.

Cell Culture, Stimulation, and Determination of ERK Phosphorylation—Rat1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and antibiotics. Subconfluent cells were serum-starved (0.1% FBS, 16 h) and stimulated with various stimuli. The treated cells were washed twice with phosphate-buffered saline (PBS) and once with buffer A (50 mM β-glycerophosphate, pH 7.3, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mM sodium orthovanadate). Cells were lysed in radioimmune precipitation assay buffer (25 mM Tris, pH 7.4, 150 mM KCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) for 5 min on ice. The lysates were centrifuged (20,000 x g, 15 min 4 °C). Similar amounts of proteins from each fraction were subjected to SDS-PAGE and Western blotting with relevant Abs and developed with either nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate or ECL.

Preparation of Immobilized ERK2 Columns—To prepare the columns, cDNA of human ERK2 was inserted into the BamH1 site of pGEX-2T (AP Biotech), fusing it to the C terminus of GST. GST-316A-ERK2 was prepared by inserting the appropriate cDNA (7) into the same sites instead of the wild type (wt) ERK2. BL21 bacteria were transformed with the GST-wtERK2, GST-316A-ERK2, and pGEX-2T constructs. For preparation of immobilized doubly phosphorylated, activated ERK2 (GST-actERK), the GST-wtERK2 was coexpressed with constitutively active MEK1 ({Delta}N-EE-MEK1 (12)) and then treated as the other constructs. Bacterial pellets were suspended in storage buffer (5 µg/ml leupeptin, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride), lysed by sonication (7 times 20 s), and then left shaking with 1% Triton X-100 at 4 °C for 30 min. Glutathione-Sepharose 4B beads (Amersham Biosciences) were added to the lysed bacteria, and after 1 h of incubation the beads were washed twice with PBS and once with 1 mg/ml BSA in storage buffer. The GST-ERK2 column contained mainly non-phosphorylated ERK2 but also mono-Tyr(P) ERK2. The immobilized GST-ERK2 was readily phosphorylated by active MEK1 in vitro, indicating that the enzyme was properly folded. The GST-actERK2 column contained about 65% doubly phosphorylated ERK2 but also mono-Tyr(P) and some (10%) non-phosphorylated ERK2. Moreover, the immobilized GST-actERK2 demonstrated substantial activity toward MBP (~200 nmol/min/mg), indicating proper folding. To initialize the experiments, the amount of glutathione-bound proteins in the column was equilibrated (~250 µg/0.5 ml beads), and the columns were extensively washed with buffer A and buffer A + 1.0 M NaCl to remove residual nonspecific binding of bacterial proteins.

Loading and Development of the GST-ERK2 Columns—Rat1 cells (2.5 x 108 cells for each column) were serum-starved (0.1% FBS, 16 h) and then treated as described. Subsequently, the cells were washed twice with PBS and once with buffer H (buffer A + protease inhibitors), and the cells were harvested into buffer H. Extracts (containing cytoplasmic and nuclear fractions) were prepared by sonication (3 x 20 s) followed by centrifugation (20,000 x g, 15 min), which yielded 3 mg of total extract in 3 ml buffer H. The extracts were precleared on GST-glutathione beads (0.5 ml) and loaded on the various columns described above at 0.5 ml/min. The columns were washed with 10 column volumes buffer A followed by 4 column volumes of 0.1 M NaCl in buffer A to release proteins that do not bind at physiological salt concentration. The remaining proteins were eluted with 0.2 M NaCl in buffer A. The columns with BAPTA-AM and ionomycin-treated extracts were developed similarly, but in keeping with the intracellular calcium concentration, 1 mM calcium was added to the ionomycin-treated extracts, whereas EGTA (1.5 mM) was added to columns of BAPTA-AM-treated extracts. The eluates were subjected to SDS-PAGE followed by silver staining or Western blotting.

Mass Spectrometry—Column eluates were subjected to SDS-PAGE, stained with Gelcode, and analyzed by the Mass Spectrometry Unit of the Weizmann Institute of Science.

Localization Studies—Rat1 cells were grown on glass coverslips under the conditions described above. After serum starvation (16 h, 0.1% FBS), the cells were treated as above, washed twice with PBS, fixed with 3% paraformaldehyde for 20 min, and permeabilized with 0.2% Triton X-100 in PBS for 5 min. Next, the cells were incubated with the relevant primary and secondary Abs, and the fluorescence imaging was performed using Nikon (EFD-3) fluorescent microscope at x400 magnification.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Interaction of ERK2, but Not Its Phosphorylated Form, with a Large Number of Proteins Is Mediated by the CRS/CD Domain—Interaction of ERKs with various cytoplasmic proteins is important for their regulation and subcellular localization (14). Here we used a proteomic approach to identify proteins that interact with ERK2 as well as with its activated, doubly phosphorylated form (actERK2) and with ERK2 mutated in its CRS/CD domain (316A-ERK2). To this end, we prepared several columns, including GST-ERK2, GST-actERK2, GST-316A-ERK2, and GST control, and used them to fractionate treated Rat1 cells. Silver staining of eluates from the GST-ERK2 column loaded with extracts from non-stimulated Rat1 cells revealed about 50 protein bands of various molecular weights (Fig. 1A). The same protein distribution was observed in eluates of extracts from cells treated with EGF for 5, 15, and 30 min (Fig. 1A, and data not shown). In contrast to the large number of proteins eluted from the GST-ERK2 column, only two bands with molecular masses of 60 and 70 kDa and a few other weak bands were detected in the eluates of GST-actERK2 column loaded with extracts from non-stimulated as well as EGF-stimulated Rat1 cells. Interestingly, also the eluates of the GST-316A-ERK2 column contained only a small number of proteins including the 60- and 70-kDa proteins seen in the GST-actERK2 and few other weak bands, different from those in the eluates of the GST-actERK2 (Fig. 1). No proteins were detected in the GST column eluates, demonstrating binding specificity.

To verify that the proteins are bound through their interaction with the residues mutated in the 316A-ERK2, we used a binding competition with CRS/CD-derived decapeptide (P2). When this peptide was added to the GST-ERK2 column during the loading and developing procedures, it competed out most of the bands seen in the regular column under the procedure used, whereas a control peptide derived from FAR1 (P1) did not change the binding and elution (Fig. 1B). Taken together, these results indicate that ERK2 binds a large number of proteins through its CRS/CD domain and that this binding may be released by the phosphorylation of ERK2. The fact that the short-term treatment with EGF does not change the binding indicates that the release is due to phosphorylation of ERKs and not due to changes in the binding proteins upon EGF stimulation.

Changes in Calcium Concentrations Modify the Repertoire of ERK2-binding Proteins—Although no changes were detected in the repertoire of ERK2-interacting proteins upon stimulation with EGF (Fig. 1) and other mitogenic agents (not shown), changes in calcium concentrations did modify the interactions. Thus, Rat1 cells were treated for short time periods with either the calcium ionophore, ionomycin, to increase intracellular calcium levels (from 100 nm to ~2 µM) or the intracellular calcium chelator BAPTA-AM to reduce intracellular calcium by about 5-fold. The extracts that were yielded from these cells were loaded on the GST columns, and the development of the columns proceeded as described above, except that 1 mM calcium was added to the columns loaded with extracts from the ionomycin-treated cells, and the development of columns loaded with extracts from BAPTA-AM-treated cells was done in the presence of EGTA (1.5 mM). Silver staining of eluates from the GST-ERK2 column loaded with extracts from BAPTA-AM-treated cells revealed a reduction in binding of many of the interacting proteins, and some of them were not detected at all (Fig. 1C). On the other hand, the eluates from ionomycin-treated cells contained largely similar proteins to those seen in eluates of non-treated or EGF-treated extracts, although the relative intensity of the protein bands was different, and some new proteins were detected. Interestingly, the GST-actERK2 eluates of BAPTA-AM-treated cell extracts contained a significant number of proteins with an overall lower intensity as compared with those eluted from non-treated Rat1 extracts. Many of these bands were different from those observed in eluates of other columns. When extracts from ionomycin-treated cells were loaded on the GST-actERK2, their eluates contained a small number of proteins, which were different from the proteins obtained in the GST-actERK2 eluates (Fig. 1C). Furthermore, as seen with extracts from untreated or EGF-treated cells, GST-316A-ERK2 was bound only to a small number of proteins. Finally, GST alone did not bind any proteins, pointing again to the specificity of the interaction. Determination of the protein levels in each of the fractions by Bradford assay correlated well with the apparent protein intensity obtained in the silver stains (Fig. 1D), indicating again that only a small number of proteins can bind to activated or 316A-ERKs and that varying calcium concentrations do modify the binding properties of both nonphosphorylated and phosphorylated ERK2.


Figure 1
View larger version (69K):
[in this window]
[in a new window]

  		FIGURE 1.
Detection of ERK2-interacting proteins by silver staining. A, extracts of quiescent or EGF-stimulated (50 ng/ml, 15 min) Rat1 cells (3 mg protein) were loaded on 0.5-ml columns of GST-ERK2, GST-actERK2, GST-316A-ERK2, and GST alone and developed as described. The 0.2 M NaCl eluates were subjected to SDS-PAGE and silver-stained. B, Rat1 extracts from non-stimulated cells were loaded on the GST-ERK2 columns in the presence of a peptide (0.5 mg/ml) derived from FAR1 (P1), from the CRS of ERK2 (P2), or without peptide, and the eluates were processed as above. C, extracts (0.5 mg protein) from BAPTA-AM (15 µM, 60 min) and ionomycin (1 µM, 30 min) were loaded on the indicated columns, which were processed in the presence of EGTA (1.5 mM, for BAPTA-AM extracts) or CaCl2 (1 mM, for ionomycin column) and processed as above. The eluates of non-treated (NT) and EGF-stimulated cells is brought for comparison. D, the protein concentrations in the various eluates were determined by Bradford protein assay. The bar graphs represent averages of three distinct experiments.

 
Identification of ERK2-interacting Proteins by Mass Spectrometry and Western Blotting—Because the ERK-interacting proteins are likely to play a role in the determination of the subcellular localization of ERKs (14), we undertook to identify the abundant interacting proteins that may serve as ERK-anchoring proteins. Thus, large amounts of eluates were subjected to SDS-PAGE followed by staining with Gelcode and identification by mass spectrometry. Proteins that clearly appear in some of the eluates were usually identified once and not in all eluates (Table 1). One big group of interacting proteins was cytoskeletal proteins, which is in agreement with the large proportion of cytoskeletal protein that were found among ERK substrates (5). Other proteins that were identified are ribosomal proteins, endocytotic proteins, few receptors, and proteins that were not categorized into any special group (Table 1). It should be noted, however, that many of the transient, physiologically relevant interactions that cannot withstand the conditions used because of lower affinity were not identified here. Therefore, the identified proteins are likely to represent only the high affinity binders, and the list of interacting proteins is probably much higher than those identified here. Moreover, the higher number of proteins identified in the ionomycin-treated cells is probably not due to changes in the number of interacting proteins (Fig. 1C) but, rather, can be the result of an easier mass spectroscopy detection of these proteins.


View this table:
[in this window]
[in a new window]

  		TABLE 1
ERK-interacting proteins

Proteins binding to ERK or pERK in different calcium concentrations were identified by Western blotting or mass spectrometric analysis. G3PD, glyceraldehyde-3-phosphate dehydrogenase.

 
Several proteins have previously been reported to interact with ERKs in different cell lines and conditions (14). To confirm interactions with ERK2, we subjected the different eluates to Western blotting using Abs to either reportedly interacting or effector proteins or the proteins identified by mass spectrometry. Two of these proteins are ERKs themselves that were reported to homodimerize upon activation (33). Here we found that only ERK1 is capable of interacting with non-activated ERK2 but not with the doubly phosphorylated enzyme, and this interaction occurs regardless of the calcium levels or stimulation (Fig. 2A). MEKs (34) as well as their phosphorylated forms were found in eluates of GST-ERK2 but not GST-actERK2 and were stronger in eluates of ionomycin-treated but were not found in eluates of BAPTA-AM-treated cell extracts. Elk1 (35) was found primarily in eluates of either non-phospho- or phospho-ERK2 loaded with BAPTA-AM-treated cell extracts, but pElk1 was not detected under any of the conditions used. RSK (36) interacted with ERK2 but not with its phospho form, with no effect of EGF or calcium, and this interaction was not seen with phosphorylated RSK. c-Fos was found to interact with non-phosphorylated ERK2 mainly when stimulated with EGF or ionomycin and less with non-stimulated or BAPTA-AM-treated extracts. Several other proteins that were found to interact with ERK2 under some conditions are KSR, CaMKII, MKP1, p38MAPK, vinculin, hnRNP-K, NUP153, and tubulin (Fig. 2B). Proteins that were not detected under any conditions are: Src, Lyn, Fyn, Syk, MKP3, protein kinases C and D, AKT, p27Kip, Jun, Myc, peroxisome proliferator-activated receptor {gamma}, estrogen receptor, and β-arrestin.

The ERK2 Interactions Are Direct and Specific—The results above clearly demonstrate that a large number of different proteins interact with ERK2 under varying conditions. To examine the possibility that the interaction is mediated via few proteins that are complexed with the additional proteins observed, we used fractionation of the eluates of the GST-ERK2 on a Superose-6 fast protein liquid chromatography sizing column. The size exclusion profile showed homogenous distribution of proteins in molecular masses of 10,000–500,000 kDa, which is in correlation to the silver stains of these eluates (data not shown). Therefore, it is likely that the interactions were not through aggregation but probably through a direct association.

To further confirm the specificity of the binding, we performed in vitro binding experiments. We chose three of the identified proteins, MEK1, vinculin, and Elk1, and examined the nature of their molecular interactions with GST-ERK2 or GST-actERK2 with varying calcium concentrations (Fig. 3). Under these conditions MEK1 interacted stronger with nonphosphorylated ERK2, and this interaction was increased with elevated calcium concentration. Vinculin showed a similar binding profile to that of MEK1, whereas Elk1 binding was detected under all conditions but was slightly higher in lower calcium concentrations. These results, which were similar with the endogenous proteins, indicate that the interactions are direct and can be observed in the absence of additional proteins.


Figure 2
View larger version (68K):
[in this window]
[in a new window]

  		FIGURE 2.
Identification of ERK2-interacting proteins by Western blotting. The eluates described in Fig. 1 were subjected to Western blot analysis with the indicated Abs. The blots were developed as described. NT, not treated; B, BAPTA-AM; I, ionomycin; E, EGF.

 


Figure 3
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 3.
In vitro binding of MEK1, vinculin, and Elk1 to ERK2. 1 µg of recombinant GST-ERK2 was incubated with 0.5 µg of recombinant His-MEK1, purified vinculin, or recombinant Elk-1 (1 h at 23 °C) in buffer containing 20 mM HEPES, pH 7.4, 20 mM MgCl2, 20 mM NaCl, 1 mM dithiothreitol, and 10 mg/ml aprotinin with the indicated concentration of CaCl2. The beads were washed 3 times with a buffer containing 20 mM HEPES, pH 7.4, 20 mM MgCl2, 100 mM NaCl, and 1 mM dithiothreitol with the same CaCl2 concentrations. Then the beads were boiled in sample buffer and subjected to Western blotting with anti-MEKs, vinculin, and Elk-1 Abs. Total loading was detected by polyclonal anti-GST Ab.

 
Decreasing Intracellular Calcium Concentrations Enhances Nuclear Translocation of ERKs in Rat1 Cells—As described above, the subcellular localization of ERKs may be regulated by protein-protein interactions. We demonstrated here that calcium profoundly affects protein interactions of ERK2 (Figs. 1 and 2), including proteins that may affect the subcellular localization of ERKs such as MEK1 and vinculin (Fig. 3) that direct ERKs to the cytoplasm (Ref. 7 and data not shown). Therefore, we hypothesized that calcium may determine the subcellular localization of ERKs and undertook to study the effects of varying calcium concentrations on the translocation of ERKs into the nucleus. As expected, ERKs were detected in the cytoplasm of resting Rat1 cells, whereas EGF stimulation resulted in translocation of ERKs into the nucleus (Fig. 4A). Interestingly, BAPTA-AM caused a slow but steady nuclear accumulation that peaked within 1 h and remained high for several hours. Pretreatment with BAPTA-AM before EGF stimulation significantly enhanced the nuclear translocation of ERKs, which was maximal 5 min after EGF stimulation and remained high at all times tested.

Because nuclear translocation of ERKs seems to be linked to their TEY phosphorylation (19), it was important to study the role of this phosphorylation in BAPTA-AM-induced nuclear localization of ERKs. Western blotting with anti-pERK Ab revealed that treatment of cells with BAPTA-AM induces a low level of ERKs phosphorylation (Fig. 4B). Moreover, pretreatment with BAPTA-AM before stimulation with EGF resulted in enhanced phosphorylation of ERKs. To determine whether the increased ERKs translocation is a result of enhanced phosphorylation, we defined activation conditions using EGF alone or BAPTA-AM plus EGF that produced equivalent amounts of pERKs (Fig. 4C). Staining of these cells with anti-general ERK Ab demonstrated that despite the comparable levels of ERKs activation, the nuclear translocation of ERKs was much more extensive in cells pretreated with BAPTA-AM than in those stimulated with EGF alone (Fig. 4D). Thus, the nuclear translocation caused by decreased intracellular calcium concentrations is probably independent of the effect of reduced calcium on the activation of ERKs.

Increasing Intracellular Calcium Concentrations Inhibits Nuclear Translocation of ERKs—Next, the effect of increasing intracellular calcium concentrations on ERKs activation and subcellular localization was examined. An increase in intracellular calcium concentrations was achieved by treatment of the cells with the calcium ionophores ionomycin and A23187 [GenBank] that have previously been shown to induce a 10–15-fold elevation in the amount of free calcium in Rat1 cells (37). However, neither ionomycin (Fig. 4E) nor A23187 [GenBank] (not shown) induced nuclear translocation of ERKs under any of the conditions examined. Furthermore, the addition of ionomycin (Fig. 4E) or A23187 [GenBank] (not shown) before EGF stimulation inhibited the EGF-induced nuclear translocation of ERKs in a dose-dependent manner, although some accumulation of ERKs was detected in the perinuclear region of the Rat1 cells. Interestingly, this inhibition occurred despite substantial activation of ERKs by ionomycin or A23187 [GenBank] , which was comparable with the EGF-induced phosphorylation (Fig. 4F). Although it is well established that ERK activation causes its nuclear translocation (19), here we uncouple these effects, as the ionomycin-induced activation of ERKs was not accompanied by their nuclear translocation. The fact that an increased amount of calcium induces cytoplasmic retention, whereas much lower calcium elevation that is induced by EGF did not inhibit the translocation and reduction in the basal calcium levels by BAPTA-AM facilitated it, strongly links calcium to the mechanism controlling the subcellular localization of ERKs.


Figure 4
View larger version (76K):
[in this window]
[in a new window]

  		FIGURE 4.
Subcellular localization of ERKs in response to variable calcium concentrations. A, after serum starvation (0.1% FBS, 16 h), Rat1 cells were treated with BAPTA-AM (15 µM) for varying times, with EGF (50 ng/ml for 15 min), or pretreated with BAPTA-AM before EGF stimulation for the final 15 min of the treatment. The cells were stained with anti-ERK Ab, and its localization was assessed by fluorescence microscopy. B, cell lysates were subjected to SDS-PAGE and Western blot analysis using Abs to pERK (upper panel) or general ERK (lower panel). C, Rat1 cells were treated with 15 µM BAPTA-AM for 1 h before stimulation with 5 ng/ml EGF or with 100 ng/ml EGF alone. Lysates were subjected to Western blotting with anti-pERK Ab. D, Rat1 cells were treated with 100 ng/ml EGF for 15 min, BAPTA-AM for 60 min, and 5 ng/ml EGF for 15 min, and the localization of ERK was assessed with anti-general ERK Ab. E, Rat1 cells were treated for 30 min with varying concentrations of ionomycin (iono) alone or before EGF stimulation (50 ng/ml, 15 min). The localization of ERK was assessed with anti-general ERK Ab. F, cell lysates were subjected to Western blot analysis using anti-pERK (upper panel) or general ERK (lower panel) Abs.

 


Figure 5
View larger version (61K):
[in this window]
[in a new window]

  		FIGURE 5.
Calcium concentrations affect the subcellular localization of active ERKs. A, Rat1 cells were stimulated with EGF (50 ng/ml, 15 min) or BAPTA-AM (15 µM) or pretreated with BAPTA-AM before EGF stimulation (15 min). B, Rat1 cells were stimulated with EGF (50 ng/ml, 15 min) or ionomycin (Iono, 1 µg/ml, 45 min) or pretreated with ionomycin (30 min) before to EGF (15 min). Localization of pERK was detected with the appropriate Ab. C, Rat1 cells were stimulated with EGF (50 ng/ml) or with ionomycin (1 µg/ml) for the indicated times. The cells were then harvested, and their extracts were subjected to Western blot analysis with the indicated Abs.

 
Calcium Modifies the Localization of pERKs—The above results indicate that calcium plays a role in the determination of ERK localization independent of their activity, but its effect on phosphorylated ERKs was not determined. To address this issue, anti-pERK Ab was used to stain Rat1 cells both before and after mitogenic stimulation and modulation of intracellular calcium concentrations. In untreated Rat1 cells, the staining with this Ab was very faint and localized primarily to the cytoplasm (Fig. 5, A and B). Stimulation of the Rat1 cells with EGF for 15 min increased pERK staining in the cytoplasm without a matching increase in the staining of the large amount of nuclear translocated ERKs at this time (Fig. 4). This low level of nuclear pERKs at later stages after stimulation has previously been reported (38) and is probably due to specific phosphatases in the nucleus. We then studied the influence of calcium and found that after BAPTA-AM treatment, pERKs translocated into the nucleus at a similar rate as the nuclear translocation of general ERKs under the same conditions (Fig. 5A). Moreover, treatment with BAPTA-AM before EGF stimulation also resulted in a time-dependent nuclear accumulation of pERKs, which was more extensive than that observed in cells treated with EGF or BAPTA-AM alone. These results suggest that the dephosphorylation of ERKs in the nucleus may be calcium-dependent or that in the absence of calcium ERKs are sequestered from phosphatases.

We then examined the effect of calcium on pERKs localization using ionomycin that enhances phosphorylation of ERKs but inhibits their nuclear translocation (Fig. 4, D and E). As expected, staining experiments detected an increase in ERKs phosphorylation upon elevated calcium concentration (Fig. 5B). However, in these ionomycin-treated cells, pERKs were mainly detected in the cytoplasm and around the nucleus, with much less nuclear staining than would be expected from the amount of ERK phosphorylation. The similar localization observed with anti-phospho and anti-general ERK Abs under high calcium conditions (Figs. 4E and 5B) is distinct from the differential staining seen with low calcium concentrations (Figs. 4A and 5A). This suggests that the inactivation of ERKs is not enhanced by high calcium concentrations and that the cytoplasmic localization caused by elevated calcium concentrations occurs independently of the phosphorylation state of ERKs. To further validate the effect of calcium on ERK localization, we examined the phosphorylation of cytoplasmic (RSK) as compared with nuclear (Elk1) ERK substrates (5). As expected, treatment of Rat1 cells with ionomycin induced a strong and sustained RSK activation that was higher than RSK phosphorylation obtained upon EGF stimulation which induces similar ERK phosphorylation (Fig. 5C). On the other hand, the ionomycin-activated ERKs did not induce Elk1 phosphorylation despite the ability of EGF-stimulated ERKs, which were similarly TEY-phosphorylated, to induce significant Elk1 phosphorylation. Therefore, these results suggest that elevated calcium concentrations may direct active ERKs to cytoplasmic and not nuclear targets and thereby modify the signaling specificity and downstream effects of ERKs.

LPA Induces a Delayed Nuclear Translocation of ERKs in a Calcium-dependent Mechanism—To study the physiological function of the calcium-induced cytoplasmic retention of ERKs, we used LPA, which was shown to increase calcium concentrations, ERK activity, and DNA synthesis in Rat1 cells (39). To this end, Rat1 cells were starved for 16 h and treated with either LPA (4 µg/ml) or EGF (50 ng/ml) for the indicated times. Western blots with anti-pERK Ab showed that ERK phosphorylation upon LPA treatment is very similar to that upon EGF stimulation, as it peaks to similar levels 5 min after stimulation and starts to decline 25 min later (Fig. 6A). Interestingly, the rate of LPA-induced nuclear translocation of ERKs was significantly delayed as compared with that induced by EGF (Fig. 6B). The addition of BAPTA-AM to LPA before stimulation by LPA enhanced the rate of translocation, similarly to the rate induced by EGF (Fig. 6C) without modification of ERK activity (data not shown). Therefore, we suggest that elevated calcium concentrations delay the rate of nuclear translocation and thereby allow ERKs to first induce cytoplasmic processes and only later, their nuclear functions. These differences in localization can induce distinct physiological functions without changes in the rate or magnitude of ERKs phosphorylation or activity.


Figure 6
View larger version (52K):
[in this window]
[in a new window]

  		FIGURE 6.
LPA delays the nuclear translocation of ERKs in a calcium-dependent manner. A, serum-starved Rat1 cells were treated with LPA (4 µg/ml) or EGF (50 ng/ml) for the indicated times. Then the lysates were subjected to Western blot analysis using {alpha}pERK or {alpha} general ERK Ab as indicated. B, After serum starvation, Rat1 cells were treated with LPA (4 µg/ml; left) or EGF (50 ng/ml) for the indicated times. Localization of ERKs and the nuclei were detected by staining with {alpha} general ERK Ab or with 4',6-diamidino-2-phenylindole (DAPI), respectively. C, serum-starved Rat-1 cells were treated with or without BAPTA-AM (BAPTA; 15 min) before stimulation with LPA (4 µg/ml, 5 min). Localization of ERKs and nuclei was detected as in B. DMSO, Me2SO.

 


Figure 7
View larger version (44K):
[in this window]
[in a new window]

  		FIGURE 7.
Nuclear translocation of GST-ERK in vitro is affected by calcium. A, HeLa and Rat1 cells were serum-starved (16 h 0.1% FBS), washed in ice-cold buffer as described (21), and permeabilized with digitonin (60 µg/ml, Calbiochem) for 5 min on ice. Cells were then washed and incubated with 0.3 mg/ml recombinant GST-actERK2 (eluted from the glutathione beads with reduced glutathione) for 30 min at room temperature. The cells were then fixed with 3% paraformaldehyde at 23 °C and methanol/acetone (50% v/v 30 min, 23 °C). After fixation, the cells were stained with anti-general ERK Ab as above. DAPI, 4',6-diamidino-2-phenylindole. B, recombinant NUP153 (0.5 µg/binding assay) was incubated (2 h, 4 °C) with GST-ERK2 conjugated to glutathione beads in the absence or presence of increasing calcium concentrations as indicated. After incubation, the beads were washed 3 times with buffer A + 0.15 M NaCl containing the indicated calcium concentration, and this was followed by boiling in sample buffer and Western blot with anti-ERK and anti-NUP153 Abs.

 
Calcium Inhibits Nuclear Translocation of ERKs by Preventing Their Nuclear Transport Machinery—The results described above raised the question as to what could be the molecular mechanism responsible for calcium-mediated inhibition of nuclear translocation. We, therefore, undertook to examine the effect of calcium on the shuttle of ERKs through the nuclear envelope that is mediated by a carrier-independent mechanism (21, 22). We used a digitonin permeabilization method in which cellular membranes, but not the nuclear envelope, are solubilized. This method was proven useful in the study of ERK translocation without affecting other cellular processes (21). We found that the addition of GST-ERK2 to the permeabilized Rat1 and HeLa cells followed by staining with anti-ERK Ab resulted in a rapid accumulation of GST-ERK2 in essentially all (>95%) detected intact nuclei (Fig. 7). However, when incubated in the presence of increasing calcium concentration, the nuclear accumulation was inhibited, and GST-ERK2 was detected mainly in perinuclear regions. This inhibition of nuclear accumulation was seen in a great majority (>90%) of the nuclei. These results indicate that the effect of calcium on ERK translocation occurs mainly at the nuclear envelope. This is supported by the perinuclear staining of ERKs observed with elevated amounts of calcium in the in vivo staining above (Figs. 4 and 5). Thus, our results indicate that the inhibition of ERK translocation by elevated calcium concentration is mainly mediated by calcium-dependent inhibition of nuclear transport through the nuclear envelope.

It was previously shown that ERKs translocate into the nucleus through the nuclear pores at the nuclear envelope by interaction with NUPs 153 and 214 (21, 22). Therefore, the accumulation of ERKs at the nuclear envelope prompted us to study the effect of calcium on the interaction of active ERKs with NUPs. For this purpose we preformed an in vitro binding assay between GST-actERK2 and His-Nup153c in the presence or absence of calcium. We found that the addition of calcium resulted in an increase in the interaction between the two proteins (Fig. 7C). Therefore, it is likely that under high calcium concentration, the fully activated ERKs that are released from their anchoring proteins do not translocate into the nucleus because of increasing irreversible interaction with NUPs. However, because calcium may increase protein interactions of inactive and to some extent also active ERK2 with other proteins, we cannot exclude the possibility that the prevention of translocation by calcium is also mediated to some extent by increased cytoplasmic retention by calcium-dependent anchoring proteins.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
A plethora of extracellular stimuli are translated by cells into intracellular responses by a network of signaling pathways. This network seems to regulate different and sometime even contradicting responses, raising the question of how the specificity of the signals is regulated. One way by which the specificity of signals can be secured is through protein-protein complexation and compartmentalization of special components of the network that bring about the right signals to their accurate destinations. Here we show that indeed the interaction of ERK2 with different proteins may regulate its differential localization and function under distinct stimulation and cellular responses. Thus, we found that non-phosphorylated ERK2 interacts with a large number of proteins through its CRS/CD domain. On the other hand, the doubly phosphorylated, active form of ERK2 loses its binding properties and seems to interact with only a small number of proteins that include its direct substrates. Most of the interactions identified are dependent on sufficient levels of calcium, which seems to enhance mainly the multiple interactions of the non-phosphorylated protein. Lower levels of calcium seem to weaken the binding of non-phosphorylated ERKs to many of the interacting proteins but may induce other types of interactions by active ERKs.

Phosphorylation and activation of ERK2 as well as changes in calcium concentrations not only modify the magnitude of protein interaction to ERK2 but also affect the subcellular localization of the ERKs. Thus, we show here that an additional regulator of ERK translocation is varying calcium levels, which when reduced, increase nuclear translocation, whereas elevated calcium levels prevent the translocation. The effects described here on the protein-protein interactions of ERK2 may explain the regulation of the subcellular localization of ERKs according to the following model (Fig. 8); in resting cells, ERKs are localized in the cytoplasm due to calcium-dependent interactions with a large number of proteins, which direct them to various areas in the cytoplasm. Upon activation, ERKs detach from most of their cytoplasmic anchoring proteins and are free to phosphorylate their substrates. The active ERK molecules are also able at this stage to translocate into the nucleus where they accumulate by binding to a nuclear set of interacting proteins. Elevated calcium concentrations do not interfere with the release of ERKs from the cytoplasmic anchoring proteins but seem to inhibit the penetration of the free pERK molecules into the nucleus, probably due to inhibition of the nuclear transport machinery. Consequently, active ERK molecules can influence cytoplasmic processes for longer times but cannot induce short-term effects (e.g. transcription) in the nucleus. Finally, the reduction of calcium below physiological levels disrupts the calcium-dependent interactions of ERKs and allows non-phosphorylated ERKs to move into various cellular compartments where the ERKs interact with a different set of proteins in a calcium-independent manner.

An important issue in this study was to determine the specificity of the interactions with ERK2. Several lines of evidence lead to the conclusion that most of the identified proteins indeed bind directly to ERK2. Thus, we found the following. (a) Most of the proteins eluted from the GST-ERK2 column as free proteins and not as aggregates, indicating that they were not bound through large protein complexes. (b) Some of the interactions identified (MEK1, vinculin, Elk1) were reproduced in an in vitro purified system in the absence of any other proteins. (c) No proteins were found to bind to either GST alone or even to the GST-316A-ERK2, which is mutated in only three residues within the CRS/CD domain. (d) Many of the proteins examined, including some that were reported as "sticky proteins" failed to bind to GST-ERK2. (e) Another method to determine protein-protein interaction, the yeast two-hybrid system, also revealed a large number of ERK-interacting proteins (>100, data not shown). (f) It has previously been shown in many works that ERKs interact with substantial number of proteins including scaffolds, substrates, and others (5, 40). Taken together, these observations strongly indicate that most, if not all, of the identified interactions are indeed through direct and specific binding with ERK2.

As mentioned above, several ERK-interacting proteins have been identified over the past years, and therefore, it was important to analyze their interaction in the context of large number of other interacting proteins. Thus, it was shown that the protein interaction of ERKs is mediated by several regions including CRS/CD (7, 8), the DEF binding domain (41), non-phosphorylated activation loop residues (9), and others (for review, see Ref. 40). It was also shown that the interaction between ERKs and MEKs is reversed upon stimulation (19) and, thus, allows nuclear translocation. Here we confirm these observations by showing that the interaction of MEKs occurs only with non-phosphorylated ERK2 but not with the phosphorylated ERK2. We also show that the MEK-ERK interaction is dependent in part on elevated calcium concentrations. Thus, our results suggest that MEKs are not the only cytoplasmic anchoring proteins of ERKs but rather belong to a group of CRS/CD interactors that keep ERKs in the cytoplasm.

Homodimerization of active ERK molecules was proposed to participate in the mechanisms of translocation of ERKs (33). However, we found here that interaction between ERKs occurs only in their non-phosphorylated form, and calcium has only a minor effect on these interactions. These results together with the fact that substitution of the homodimerization domain to alanines enhanced rather than slowed the nuclear translocation of ERKs (19) challenge the role of ERK dimerization in the nuclear translocation process. Another known interaction of ERKs is with the transcription factor Elk-1 (35). We found that Elk1 interaction occurs with unphosphorylated as well as phosphorylated ERK2 but not with the phosphorylated form of Elk1. These results indicate that ERKs interact with Elk1 upon activation, and the proteins are detached upon Elk1 phosphorylation. In addition, we expected to find an interaction with MAPK phosphatases (43) but found MKP1 binding only after ionomycin treatment. The reason for the lack of MKPs interaction is probably because they are only expressed upon stimulation (44). Thus, in the starved cells there were no MKPs, and the short ionomycin treatment was sufficient to induce only MKP1.


Figure 8
View larger version (42K):
[in this window]
[in a new window]

  		FIGURE 8.
Model representing ERKs localization upon stimulation and changes in calcium concentrations. Localization, phosphorylation, and interaction of ERKs are shown under the conditions studied in this work. For more details, see "Discussion."

 
In contrast to most of the ERK-interacting proteins that could bind to non-phosphorylated ERK2, there were only few proteins that were found to interact under the conditions examined. One of these proteins is tubulin, which has previously been shown to interact with a significant portion of ERK molecules in many cells (15). This interaction was reported to be only slightly reduced upon stimulation (15), and this is confirmed here. Similar results were seen with actin, which was also reported to interact with ERKs under some conditions (45). Therefore, tubulin, actin, and other cytoskeletal elements may serve as cytoplasmic anchors of ERK2 even after stimulation, thus allowing some of the ERK molecules to execute essential functions in the cytoskeleton. Such an anchoring effect could be mediated by vinculin, which we show here to strongly interact with non-phosphorylated ERK2. Indeed, our data indicate that this protein, when overexpressed, can retain overexpressed ERK2 in the cytoplasm (data not shown), supporting its role in the regulation of ERKs localization. Finally, we found that previously reported interactions with KSR (46), RSK (36), c-Fos (47), p38MAPK (48), vimentin (49), NUP153 (22), and the newly discovered CaMKII and vinculin are increased by elevated calcium concentration. On the other hand, the interaction with the nuclear hnRNP-K (50) seems to occur mainly when calcium is missing.

The substantial effect of calcium on ERKs is likely to be of high physiological significance. Here we show that calcium delays the nuclear translocation of ERKs upon LPA treatment in a calcium-dependent manner, suggesting that ERKs can first execute their cytoplasmic function and only at late stages regulate nuclear processes. Indeed, we have shown that in the presence of calcium, ERKs were able to activate their cytosolic substrate RSK for longer period of time, whereas the phosphorylation of the nuclear substrate Elk1 was significantly reduced. This adds to the multiple effects that calcium can play in activating the ERK cascade in various cell types (26). Another example that can be re-examined in light of this work is the pituitary, where calcium levels are increased dramatically upon gonadotropin-releasing hormone stimulation. Reduced calcium concentrations only slightly decreased EGF or gonadotropin-releasing hormone-induced activation of ERKs in the pituitary-derived {alpha}3T-1 cells (51), although calcium seems to be required for the proper functioning of the ERK pathway in these cells (52). We also found that in other pituitary-derived cells termed LβT2, the translocation of ERKs into the nucleus is slow, starts only 30 min after activation, and is maximal about 90 min after stimulation. These subcellular localizations correlate with the function of ERKs in that initially (30 min) ERKs participate in the regulation of cytoplasmic exocitosis of LH or FSH (53), whereas ERK-regulated transcription can be detected only later (60–90 min (54). Thus, in these cells calcium regulation of ERK localization is important for proper outcome of gonadotropin-releasing hormone signaling.

The effect of calcium on the nuclear translocation of ERKs, which is the main physiological response identified here, drew our attention to the molecular mechanism by which the prevention of nuclear translocation occurs. When addressing the role of calcium in nuclear translocation, it is important to note that calcium may have a general role on the sliding of proteins through nuclear pores (55, 56). The mechanism that mediates this effect on nuclear pores involves a release of calcium from stores located in the cisternal space of ER that is adjacent to the nuclear envelope. This release of calcium induces a large conformational change in the nuclear pores, which then affects free nuclear diffusion. Although this mechanism might be involved in part in the prevention of ERKs translocation in our system, it cannot explain the effect on the stimulated, energy-dependent translocation observed here. Rather, this effect may be mediated by the effect of calcium on NUPs that has been previously shown as a crucial step in the translocation of ERKs into the nucleus (21, 22). Indeed, we found that ERK2 interact with Nup153, and this interaction is regulated by elevated calcium concentrations. It is, therefore, possible that high calcium concentrations may affect both passive and active mechanisms of ERK translocation into the nucleus (42). Calcium-induced conformational changes (55) may affect the diffusion of ERKs, which occurs mainly in resting cells, and increased association of active ERKs with NUPs may explain the prevention of the stimulated translocation.

In summary, we found that inactive ERK2 interacts with a large number of proteins through its CRS/CD domain, whereas the pERK2 interacts with only few proteins, including some of its substrates. Changes in calcium concentrations affect protein interaction of ERKs as well as their nuclear translocation. We also showed that translocation of ERKs induced by LPA is delayed as compared with the translocation induced by EGF, and this delay is due to the elevated calcium concentrations induced by LPA. The prevention of translocation by high calcium probably occurs by inhibition of the transport of ERKs through the nuclear envelope. Together, these data are consistent with a model in which ERKs in resting cells are bound to several cytoplasmic proteins in a calcium-dependent manner. Upon stimulation, ERKs are phosphorylated and released from the cytoplasmic anchors to allow free shuttle within the cytoplasm and toward the nucleus, which is inhibited by calcium. This is physiologically important because elevated calcium by some stimuli, such as LPA, may change the localization and thereby the specificity of the ERK cascade. Thus, the subcellular localization of ERKs, which is influenced by calcium, and the CRS/CD-mediated interactions with many proteins appear to be key regulators of the ERK cascade.


   FOOTNOTES
 
* This work was supported by grants from the Israel Academy of Sciences and Humanities from the European Community's Sixth Framework Program Project IST-2004-027265-SIMAP. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 These authors are equal contributors. Back

2 An incumbent of the Yale Lewine and Ella Miller Lewine professorial chair for cancer research. To whom correspondence should be addressed. Tel.: 972-8-9343602; Fax: 972-8-9344116; E-mail: rony.seger{at}weizmann.ac.il.

3 The abbreviations used are: ERK, extracellular signal-regulated kinase; pERK, phosphorylated ERK; actERK, activated ERK; Ab, antibody; CRS, cytoplasmic retention sequence; CD, common docking; MAPK, mitogen-activated protein kinase; MKP, MAPK phosphatase: MEK, mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase kinase; NUP, nuclear pore protein; CaMK, calcium calmodulin kinase; hnRNP, heterogeneous nuclear ribonucleoprotein K; LPA, lysophosphatidic acid; FBS, fetal bovine serum; PBS, phosphate-buffered saline; GST, glutathione S-transferase. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Imajo, M., Tsuchiya, Y., and Nishida, E. (2006) IUBMB Life 58, 312–317[Medline] [Order article via Infotrieve]
  2. Avruch, J. (2007) Biochim. Biophys. Acta 1773, 1150–1160[Medline] [Order article via Infotrieve]
  3. Raman, M., Chen, W., and Cobb, M. H. (2007) Oncogene 26, 3100–3112[CrossRef][Medline] [Order article via Infotrieve]
  4. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726–735[Abstract]
  5. Yoon, S., and Seger, R. (2006) Growth Factors 24, 21–44[Medline] [Order article via Infotrieve]
  6. Shaul, Y. D., and Seger, R. (2007) Biochim. Biophys. Acta 1773, 1213–1226[Medline] [Order article via Infotrieve]
  7. Rubinfeld, H., Hanoch, T., and Seger, R. (1999) J. Biol. Chem. 274, 30349–30352[Abstract/Free Full Text]
  8. Tanoue, T., and Nishida, E. (2002) Pharmacol. Ther. 93, 193–202[CrossRef][Medline] [Order article via Infotrieve]
  9. Bendetz-Nezer, S., and Seger, R. (2007) J. Biol. Chem. 282, 25114–25122[Abstract/Free Full Text]
  10. Bardwell, L. (2006) Biochem. Soc. Trans. 34, 837–841[CrossRef][Medline] [Order article via Infotrieve]
  11. Lenormand, P., Brondello, J. M., Brunet, A., and Pouyssegur, J. (1998) J. Cell Biol. 142, 625–633[Abstract/Free Full Text]
  12. Jaaro, H., Rubinfeld, H., Hanoch, T., and Seger, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3742–3747[Abstract/Free Full Text]
  13. Fukuda, M., Gotoh, I., Gotoh, Y., and Nishida, E. (1996) J. Biol. Chem. 271, 20024–20028[Abstract/Free Full Text]
  14. Pouyssegur, J., Volmat, V., and Lenormand, P. (2002) Biochem. Pharmacol. 64, 755–763[CrossRef][Medline] [Order article via Infotrieve]
  15. Reszka, A. A., Seger, R., Diltz, C. D., Krebs, E. G., and Fischer, E. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8881–8885[Abstract/Free Full Text]
  16. Fukuda, M., Gotoh, Y., and Nishida, E. (1997) EMBO J. 16, 1901–1908[CrossRef][Medline] [Order article via Infotrieve]
  17. Blanco-Aparicio, C., Torres, J., and Pulido, R. (1999) J. Cell Biol. 147, 1129–1136[Abstract/Free Full Text]
  18. Morrison, D. K., and Davis, R. J. (2003) Annu. Rev. Cell Dev. Biol. 19, 91–118[CrossRef][Medline] [Order article via Infotrieve]
  19. Wolf, I., Rubinfeld, H., Yoon, S., Marmor, G., Hanoch, T., and Seger, R. (2001) J. Biol. Chem. 276, 24490–24497[Abstract/Free Full Text]
  20. Ranganathan, A., Yazicioglu, M. N., and Cobb, M. H. (2006) J. Biol. Chem. 281, 15645–15652[Abstract/Free Full Text]
  21. Matsubayashi, Y., Fukuda, M., and Nishida, E. (2001) J. Biol. Chem. 276, 41755–41760[Abstract/Free Full Text]
  22. Whitehurst, A. W., Wilsbacher, J. L., You, Y., Luby-Phelps, K., Moore, M. S., and Cobb, M. H. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7496–7501[Abstract/Free Full Text]
  23. Adachi, M., Fukuda, M., and Nishida, E. (2000) J. Cell Biol. 148, 849–856[Abstract/Free Full Text]
  24. Berridge, M. J., Bootman, M. D., and Roderick, H. L. (2003) Nat. Rev. Mol. Cell Biol. 4, 517–529[CrossRef][Medline] [Order article via Infotrieve]
  25. Clapham, D. E. (2007) Cell 131, 1047–1058[CrossRef][Medline] [Order article via Infotrieve]
  26. Agell, N., Bachs, O., Rocamora, N., and Villalonga, P. (2002) Cell. Signal. 14, 649–654[CrossRef][Medline] [Order article via Infotrieve]
  27. Cullen, P. J., and Lockyer, P. J. (2002) Nat. Rev. Mol. Cell Biol. 3, 339–348[CrossRef][Medline] [Order article via Infotrieve]
  28. Xia, Z., Dudek, H., Miranti, C. K., and Greenberg, M. E. (1996) J. Neurosci. 16, 5425–5436[Abstract/Free Full Text]
  29. Ginnan, R., and Singer, H. A. (2002) Am. J. Physiol. Cell Physiol. 282, 754–761
  30. Murasawa, S., Mori, Y., Nozawa, Y., Masaki, H., Maruyama, K., Tsutsumi, Y., Moriguchi, Y., Shibasaki, Y., Tanaka, Y., Iwasaka, T., Inada, M., and Matsubara, H. (1998) Hypertension 32, 668–675[Abstract/Free Full Text]
  31. Abraham, S. T., Benscoter, H. A., Schworer, C. M., and Singer, H. A. (1997) Circ. Res. 81, 575–584[Abstract/Free Full Text]
  32. Ebinu, J. O., Bottorff, D. A., Chan, E. Y., Stang, S. L., Dunn, R. J., and Stone, J. C. (1998) Science 280, 1082–1086[Abstract/Free Full Text]
  33. Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., and Cobb, M. H. (1998) Cell 93, 605–615[CrossRef][Medline] [Order article via Infotrieve]
  34. Fukuda, M., Gotoh, I., Adachi, M., Gotoh, Y., and Nishida, E. (1997) J. Biol. Chem. 272, 32642–32648[Abstract/Free Full Text]
  35. Rao, V. N., and Reddy, E. S. (1994) Oncogene 9, 1855–1860[Medline] [Order article via Infotrieve]
  36. Roux, P. P., Richards, S. A., and Blenis, J. (2003) Mol. Cell. Biol. 23, 4796–4804[Abstract/Free Full Text]
  37. Cook, S. J., Aziz, N., and McMahon, M. (1999) Mol. Cell. Biol. 19, 330–341[Abstract/Free Full Text]
  38. Yung, Y., Dolginov, Y., Yao, Z., Rubinfeld, H., Michael, D., Hanoch, T., Roubini, E., Lando, Z., Zharhary, D., and Seger, R. (1997) FEBS Lett. 408, 292–296[CrossRef][Medline] [Order article via Infotrieve]
  39. Cook, S. J., and McCormick, F. (1996) Biochem. J. 320, 237–245[Medline] [Order article via Infotrieve]
  40. Chuderland, D., and Seger, R. (2005) Mol. Biotechnol. 29, 57–74[CrossRef][Medline] [Order article via Infotrieve]
  41. Lee, T., Hoofnagle, A. N., Kabuyama, Y., Stroud, J., Min, X., Goldsmith, E. J., Chen, L., Resing, K. A., and Ahn, N. G. (2004) Mol. Cell 14, 43–55[CrossRef][Medline] [Order article via Infotrieve]
  42. Adachi, M., Fukuda, M., and Nishida, E. (1999) EMBO J. 18, 5347–5358[CrossRef][Medline] [Order article via Infotrieve]
  43. Sun, H., Charles, C. H., Lau, L. F., and Tonks, N. K. (1993) Cell 75, 487–493[CrossRef][Medline] [Order article via Infotrieve]
  44. Camps, M., Chabert, C., Muda, M., Boschert, U., Gillieron, C., and Arkinstall, S. (1998) FEBS Lett. 425, 271–276[CrossRef][Medline] [Order article via Infotrieve]
  45. Leinweber, B. D., Leavis, P. C., Grabarek, Z., Wang, C. L., and Morgan, K. G. (1999) Biochem. J. 1, 117–123
  46. Yu, W., Fantl, W. J., Harrowe, G., and Williams, L. T. (1998) Curr. Biol. 8, 56–64[CrossRef][Medline] [Order article via Infotrieve]
  47. Murphy, L. O., Smith, S., Chen, R. H., Fingar, D. C., and Blenis, J. (2002) Nat. Cell Biol. 4, 556–564[Medline] [Order article via Infotrieve]
  48. Zhang, H., Shi, X., Hampong, M., Blanis, L., and Pelech, S. (2001) J. Biol. Chem. 276, 6905–6908[Abstract/Free Full Text]
  49. Perlson, E., Hanz, S., Ben-Yaakov, K., Segal-Ruder, Y., Seger, R., and Fainzilber, M. (2005) Neuron 45, 715–726[CrossRef][Medline] [Order article via Infotrieve]
  50. Habelhah, H., Shah, K., Huang, L., Ostareck-Lederer, A., Burlingame, A. L., Shokat, K. M., Hentze, M. W., and Ronai, Z. (2001) Nat. Cell Biol. 3, 325–330[CrossRef][Medline] [Order article via Infotrieve]
  51. Reiss, N., Levi, L. N., Shacham, S., Harris, D., Seger, R., and Naor, Z. (1997) Endocrinology 138, 1673–1682[Abstract/Free Full Text]
  52. Mulvaney, J. M., Zhang, T., Fewtrell, C., and Roberson, M. S. (1999) J. Biol. Chem. 274, 29796–29804[Abstract/Free Full Text]
  53. Naor, Z., Benard, O., and Seger, R. (2000) Trends Endocrinol. Metab. 11, 91–99[CrossRef][Medline] [Order article via Infotrieve]
  54. Harris, D., Chuderland, D., Bonfil, D., Kraus, S., Seger, R., and Naor, Z. (2003) Endocrinology 144, 612–622[Abstract/Free Full Text]
  55. Lee, M. A., Dunn, R. C., Clapham, D. E., and Stehno-Bittel, L. (1998) Cell Calcium 23, 91–101[CrossRef][Medline] [Order article via Infotrieve]
  56. Erickson, E. S., Mooren, O. L., Moore, D., Krogmeier, J. R., and Dunn, R. C. (2006) Can. J. Physiol. Pharmacol. 84, 309–318[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/17/11176    most recent
M709030200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chuderland, D.
Right arrow Articles by Seger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chuderland, D.
Right arrow Articles by Seger, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement